Literature DB >> 21463284

Molecular and cellular basis: insights from experimental models of Dravet syndrome.

Kazuhiro Yamakawa1.   

Abstract

Dravet syndrome is caused by mutations of the SCN1A gene that encodes voltage-gated sodium channel alpha-1 subunit. SCN1A-knock-in mouse with a disease-relevant nonsense mutation that we generated well reproduced the disease phenotypes. Both homozygous and heterozygous knock-in mice developed epileptic seizures within the first postnatal month. In heterozygotes, trains of evoked action potentials in fast-spiking, inhibitory cells exhibited pronounced spike amplitude decrement late in the burst but not in pyramidal neurons. Furthermore, our immunohistochemical studies showed that in wild-type mice Nav1.1 is expressed in parvalbumin-positive inhibitory interneurons (PV cells), dominantly in its axons and moderately in somata, and not expressed in pyramidal cells nor other types of interneurons including somatostatin-positive and calretinin-positive cells. These results so far suggest that Nav1.1 expression is largely confined to PV cells and plays critical roles in their spike output, and that impaired function of PV cells would be the cellular basis of Dravet syndrome. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463284     DOI: 10.1111/j.1528-1167.2011.03006.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

Review 1.  Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy.

Authors:  X Jiang; M Lachance; E Rossignol
Journal:  Prog Brain Res       Date:  2016-06-07       Impact factor: 2.453

Review 2.  Pharmacotherapy for Dravet Syndrome.

Authors:  Adam Wallace; Elaine Wirrell; Daniel L Kenney-Jung
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 3.  Microcircuits and their interactions in epilepsy: is the focus out of focus?

Authors:  Jeanne T Paz; John R Huguenard
Journal:  Nat Neurosci       Date:  2015-03       Impact factor: 24.884

4.  Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation.

Authors:  Ana Ricobaraza; Lucia Mora-Jimenez; Elena Puerta; Rocio Sanchez-Carpintero; Ana Mingorance; Julio Artieda; Maria Jesus Nicolas; Guillermo Besne; Maria Bunuales; Manuela Gonzalez-Aparicio; Noemi Sola-Sevilla; Miguel Valencia; Ruben Hernandez-Alcoceba
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

Review 5.  Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention.

Authors:  Lívea Dornela Godoy; Tamiris Prizon; Matheus Teixeira Rossignoli; João Pereira Leite; José Luiz Liberato
Journal:  Front Integr Neurosci       Date:  2022-02-17

6.  Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome.

Authors:  Feng Gu; Isabel Parada; Tao Yang; Frank M Longo; David A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 11.205

7.  A human Dravet syndrome model from patient induced pluripotent stem cells.

Authors:  Norimichi Higurashi; Taku Uchida; Christoph Lossin; Yoshio Misumi; Yohei Okada; Wado Akamatsu; Yoichi Imaizumi; Bo Zhang; Kazuki Nabeshima; Masayuki X Mori; Shutaro Katsurabayashi; Yukiyoshi Shirasaka; Hideyuki Okano; Shinichi Hirose
Journal:  Mol Brain       Date:  2013-05-02       Impact factor: 4.041

Review 8.  Presynaptic long-term plasticity.

Authors:  Ying Yang; Nicole Calakos
Journal:  Front Synaptic Neurosci       Date:  2013-10-17

9.  Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome.

Authors:  J Hsiao; T Y Yuan; M S Tsai; C Y Lu; Y C Lin; M L Lee; S W Lin; F C Chang; H Liu Pimentel; C Olive; C Coito; G Shen; M Young; T Thorne; M Lawrence; M Magistri; M A Faghihi; O Khorkova; C Wahlestedt
Journal:  EBioMedicine       Date:  2016-05-13       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.